148 filings
8-K
ESPR
Esperion Therapeutics Inc.
8 May 24
Other Events
4:31pm
8-K
ESPR
Esperion Therapeutics Inc.
7 May 24
Esperion Reports First Quarter 2024 Financial Results
7:29am
8-K
ESPR
Esperion Therapeutics Inc.
27 Feb 24
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
7:23am
8-K
ESPR
Esperion Therapeutics Inc.
22 Jan 24
Esperion Announces Proposed Public Offering of Common Stock
6:10am
8-K
ESPR
Esperion Therapeutics Inc.
18 Jan 24
Regulation FD Disclosure
4:03pm
8-K
d5a6vl
11 Jan 24
Results of Operations and Financial Condition
4:09pm
8-K
zdbh9s r95q
3 Jan 24
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
8:00am
8-K
0b2b n5exesz
7 Nov 23
Esperion Reports Third Quarter 2023 Financial Results
7:30am
8-K
xiisuva 241
1 Aug 23
Esperion Reports Second Quarter 2023 Financial Results
7:07am
8-K
hbgoxlb 2pv
26 Jun 23
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
6:03am
8-K
prg6cv76zqu1npiay5wh
15 Jun 23
Departure of Directors or Certain Officers
4:56pm
8-K
ep2iuxiwet5d
9 May 23
Esperion Reports First Quarter 2023 Financial Results
7:22am
8-K
b4np0lar
4 May 23
Other Events
9:26am
8-K
s3rv she3jzu0445
27 Mar 23
Other Events
4:49pm
8-K
wv0btv
22 Mar 23
Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:40pm
8-K
x1m m9gk8p
15 Mar 23
Other Events
4:24pm
8-K
oqhe9
10 Mar 23
Regulation FD Disclosure
4:31pm
8-K
f6b qr302ghdllioo36
6 Mar 23
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin
6:04am
8-K
626ybgyc
21 Feb 23
Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
7:30am
8-K
cjtotl60kg7v 8uwgrm1
9 Jan 23
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
9:04am